Academic Journal

Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin‑2 Receptor: Structure–Activity Relationships and Optimization

التفاصيل البيبلوغرافية
العنوان: Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin‑2 Receptor: Structure–Activity Relationships and Optimization
المؤلفون: Jean-Olivier Zirimwabagabo (1743481), Ameera B. A. Jailani (9165386), Paris Avgoustou (9165383), Matthew J. Tozer (2664976), Karl R. Gibson (1262118), Paul A. Glossop (1262115), James E. J. Mills (9165389), Roderick A. Porter (9165392), Paul Blaney (9165395), Ning Wang (108353), Timothy M. Skerry (8592216), Gareth O. Richards (9165410), Joseph P. A. Harrity (7204718)
سنة النشر: 2021
المجموعة: Smithsonian Institution: Digital Repository
مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Genetics, Molecular Biology, Pharmacology, Immunology, Cancer, Inorganic Chemistry, Infectious Diseases, Computational Biology, Chemical Sciences not elsewhere classified, calcitonin receptor, CTR, RAMP, AM 2 receptors, compounds exhibit therapeutically, AM 2 antagonists, calcitonin receptor-like receptor, GPCR, receptor activity-modifying proteins, Optimization Class B G-protein-coup., CLR, AM 1 receptors, CGRP, first-in-class AM 2 receptor antago., AM 1 receptor
الوصف: Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM 1 ) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM 2 ) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM 2 receptors would be therapeutically valuable, inhibition of AM 1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM 2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM 1 receptor. These results highlight the therapeutic potential of AM 2 antagonists.
نوع الوثيقة: text
اللغة: unknown
Relation: https://figshare.com/articles/online_resource/Discovery_of_a_First-In-Class_Small_Molecule_Antagonist_against_the_Adrenomedullin_2_Receptor_Structure_Activity_Relationships_and_Optimization/14365521
DOI: 10.1021/acs.jmedchem.0c02191.ls01
الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c02191.ls01
Rights: CC BY-NC 4.0
رقم الانضمام: edsbas.25AF4196
قاعدة البيانات: BASE
الوصف
DOI:10.1021/acs.jmedchem.0c02191.ls01